- Home
- TBPH vs AACT Comparison
TBPH vs AACT Comparison
Compare TBPH & AACT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBPH
- AACT
- Stock Information
- Founded
- TBPH 2013
- AACT 2021
- Country
- TBPH United States
- AACT United States
- Employees
- TBPH N/A
- AACT N/A
- Industry
- TBPH Biotechnology: Pharmaceutical Preparations
- AACT
- Sector
- TBPH Health Care
- AACT
- Exchange
- TBPH Nasdaq
- AACT Nasdaq
- Market Cap
- TBPH 699.0M
- AACT 697.5M
- IPO Year
- TBPH N/A
- AACT 2023
- Fundamental
- Price
- TBPH $14.40
- AACT $11.40
- Analyst Decision
- TBPH Strong Buy
- AACT
- Analyst Count
- TBPH 4
- AACT 0
- Target Price
- TBPH $23.00
- AACT N/A
- AVG Volume (30 Days)
- TBPH 543.4K
- AACT 508.0K
- Earning Date
- TBPH 11-11-2025
- AACT 01-01-0001
- Dividend Yield
- TBPH N/A
- AACT N/A
- EPS Growth
- TBPH N/A
- AACT N/A
- EPS
- TBPH 0.26
- AACT 0.26
- Revenue
- TBPH $77,205,000.00
- AACT N/A
- Revenue This Year
- TBPH $79.82
- AACT N/A
- Revenue Next Year
- TBPH N/A
- AACT N/A
- P/E Ratio
- TBPH $55.89
- AACT $43.59
- Revenue Growth
- TBPH 24.49
- AACT N/A
- 52 Week Low
- TBPH $7.88
- AACT $10.79
- 52 Week High
- TBPH $14.55
- AACT $11.62
- Technical
- Relative Strength Index (RSI)
- TBPH 72.80
- AACT 50.13
- Support Level
- TBPH $13.47
- AACT $11.30
- Resistance Level
- TBPH $14.42
- AACT $11.44
- Average True Range (ATR)
- TBPH 0.41
- AACT 0.03
- MACD
- TBPH -0.05
- AACT 0.00
- Stochastic Oscillator
- TBPH 86.11
- AACT 71.43
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
About AACT Ares Acquisition Corporation II
Ares Acquisition Corp II is a blank check company.